Thai neurosurgeon Dr. Teera Tangviriyabiaboon completed the operation on an 80-year-old patient who failed conservative treatments prior to surgery.
Dr. Tangviriyabiaboon said the technology was easy to use and is “expected to maximize success of spine fusion as the only approved demineralized bone matrix and bioactive glass combination biologic.”
“NanoFUSE is clinically proven and reduces the need for autograft,” said Jake Lubinski, president of NanoFuse. “The recent release of our 100 percent fully synthetic bioactive glass strip, NanoStrip positions NanoFuse to be the worldwide leader in bioactive glass and synthetic biologics.”
More articles on biologics:
DiscGenics tests injectable disc cell therapy for degenerative disc disease
Federal court bans Florida stem cell company from treating patients, including spinal cord injury
NervGen Pharma launches MS program focusing on nerve remyelination — 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
